We've understood today how CRISPR in principle works, but sometimes the application is what limits the type of therapeutics it can be useful. Most of the clinical trials that have been used more using CRISPR has been probably more successful in what we call XVivo approaches. Or this is going to take the tissue, put it in a dish to introduce you back. So I'll give you an example. One of the first XVivo clinical trials thathave been used, and it's getting pretty close to releasing the stage three trial results. They still have to follow these patients for longer periods, but quite promising results where they have individuals, let's say, with a type of an